STOCK PICK OF 2022?
BUILT FOR GROWTH, DRIVING VALUE
One of the leading Canadian B2B post-harvest solutions providers, Ayurcann is one of the most innovative publicly traded companies in the adult and medical-use markets.
CSE:AYUR is focused on becoming the partner of choice for leading Canadian brands and yielding continuous returns for investors.
Is this your opportunity to join the $10.1 billion 2.0 market?
+1,149%
Increase In Net Revenue
$7.6mm for the fiscal year ending June 30, 2021
+440%
Increase In Operating income
$2.1mm for the fiscal year ending June 30, 2021
$2.1 Mil
Adjusted EBIDTA In 2021
Representing gross margins of approximately 60%
Get the latest investor news
MARKET OPPORTUNITY
A Rapidly Growing 2.0 Market Segment
As the 2.0 market matures, it moves away from vertical integration.
The 2.0 market is growing at an exponential rate – what’s an emerging market of today will transition into a mature industry lead by companies that specialize and develop competitive advantages in the value chain.
Ayurcann is well-positioned to capitalize on the 2.0 market evolution
Canadian 2.0 Market*
Canadian 2.0 Segment Sales Growth**
THE VALUE CHAIN
Ayurcann's Competitive Advantage
Leading 2.0 Product Manufacturer
Very low OPEX = Massive Operating Leverage
High Gross Margins
High-Margin Branded Product Offerings
EBITDA and Cash Flow Positive
Debt Free
Ayurcann is a leading extraction company in Canada, focused on providing and creating custom processes and pharma-grade products for the adult and medical use markets.
Competitive
- Extraction and Refinement
- Bulk Oil Sales
- White Label Manufacturing
CERTIFIED
- Health Canada Standard Processing Licensed
- Health Canada R&D Licensed
- Amended License for Sales to Provincial Distributors and Retailers
INNOVATIVE
- In-house R&D
- Flexible Production
- Experienced and Expert Team
- Turnkey Solutions Availability
Get the latest investor news
TOP SERVICES + TOP PRODUCTS + COMPETITIVE YET PROFITABLE PRICING =
Key Success Factors
Services to Partners & Brands
Efficient technology + infrastructure providing top quality, timely service at competitive pricing
Proven traction with over 20 clients and counting
Medicinal Line of Products
XPLOR brand serves medicinal B2B market, 6 SKUs at launch
Ayurcann Marketplace now offering direct sales to registered patients
Operational & Financial Excellence
Over $7.6 million in revenue booked in Fiscal year ending June 30, 2021
Over $2 million in adjusted EBITDA
Low OPEX relative to competitors
OFFERINGS
Competitive Product Lines
Extraction & Refinement
Processed over 16,000 kgs of biomass, to date
Ethanol extraction specialty
Low to high volume production capabilities
Fast and flexible production
Bulk Oil Sales
Secured monthly biomass supply
Over 300 kg monthly distillate inventory
Inventory-to-supply leading license producers, supporting edibles, topicals, and inhalables
Quality supply of crude, distillate, and isolates
White Label Manufacturing
In-house developed IP formulation
20+ product offering SKUs
Custom extracts and formulations
Branding and packaging capabilities
Get the latest investor news
© 2021 Ayurcann Inc. All Rights Reserved.
NO INVESTMENT ADVICE
